---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-26-000031"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:49:26.489410+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolent Health Reports Q1 2026 Results; Revenue Up, Net Loss Narrowed

## Summary
- Revenue $496.2M vs $483.6M in Q1 2025; net loss improved to $26.6M from $72.3M.
- Adjusted EBITDA $22.1M with margin 4.4%, down from $36.9M margin 7.6% prior year.
- Signed new revenue agreements: advanced imaging solution for ~4.5M lives; oncology/cardiology expansion expected >$200M annual revenue.
- CEO Seth Blackley highlighted successful oncology launches at Highmark and Aetna, focus on AI opportunity.
- Medical expense ratio rose to 93.3% from 68% (84% excluding Evolent Care Partners).

## SEC filing metadata
- accession: 0001628908-26-000031
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890826000031/0001628908-26-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890826000031/evh-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-26-000031
- JSON: https://secwatch.observer/filing/0001628908-26-000031.json
- Plain text: https://secwatch.observer/filing/0001628908-26-000031.txt

## Source-grounded claims
- claim_id: 85e75739dc7aaa5dd74f36047ee7a6b8b8f17d36
  claim: Evolent Health, Inc. reported quarter ended March 31, 2026 results: revenue $496,246, net income $(26,632).
  evidence_excerpt: March 31, 2026 include (dollars in thousands, except for average PMPM fees and revenue per case): For the Three Months Ended March 31, 2026 2025 Financial Results: Revenue $ 496,246 $ 483,649 Net loss attributable to common shareholders of Evolent Health, Inc. $ (26,632) $ (72,250) Net loss margin (5.4) % (14.9) % Adjusted EBITDA $ 22,067 $ 36,860 Adjusted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890826000031/0001628908-26-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.